Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedAug 31, 2025
DataAggregated Company Financials
Companies549
  • 7D-1.8%
  • 3M8.2%
  • 1Y-9.9%
  • YTD4.5%

Over the last 7 days, the Biotech industry has dropped 1.8%, driven by a pullback from Amgen of 2.0%. The industry has fallen 9.9% in the last year. Looking forward, earnings are forecast to grow by 26% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 31 Aug 2025US$1.1tUS$163.5b-US$18,374,916,758.5615.4x-57.4x6.5x
Tue, 29 Jul 2025US$992.7bUS$155.1b-US$22,907,102,966.3914.7x-43.3x6.4x
Thu, 26 Jun 2025US$932.5bUS$156.0b-US$23,833,808,017.7716.8x-39.1x6x
Sat, 24 May 2025US$908.4bUS$155.9b-US$24,112,206,612.1115.6x-37.7x5.8x
Mon, 21 Apr 2025US$756.9bUS$119.2b-US$36,619,881,205.0719.4x-20.7x6.3x
Wed, 19 Mar 2025US$848.7bUS$118.4b-US$37,468,766,996.5019.6x-22.6x7.2x
Fri, 14 Feb 2025US$828.4bUS$118.3b-US$35,648,753,290.5717.4x-23.2x7x
Sun, 12 Jan 2025US$947.8bUS$149.4b-US$26,263,014,335.7116.6x-36.1x6.3x
Tue, 10 Dec 2024US$1.0tUS$150.0b-US$26,481,719,164.0717.7x-39.1x6.9x
Thu, 07 Nov 2024US$1.1tUS$148.4b-US$30,716,238,423.6717.2x-35.3x7.3x
Sat, 05 Oct 2024US$879.9bUS$113.1b-US$35,952,253,973.7722x-24.5x7.8x
Mon, 02 Sep 2024US$909.4bUS$113.1b-US$35,712,101,098.3824x-25.5x8x
Wed, 31 Jul 2024US$1.2tUS$164.9b-US$28,962,809,067.1126.4x-42.6x7.5x
Fri, 28 Jun 2024US$1.1tUS$164.4b-US$27,987,328,341.4127.9x-41x7x
Sun, 26 May 2024US$1.1tUS$164.6b-US$26,653,350,594.7223.8x-42.2x6.8x
Tue, 23 Apr 2024US$1.1tUS$164.2b-US$23,311,155,066.5220.4x-45.9x6.5x
Thu, 21 Mar 2024US$1.2tUS$164.4b-US$23,861,120,065.0121.1x-48.9x7.1x
Sat, 17 Feb 2024US$1.2tUS$169.1b-US$20,461,379,458.5815.7x-57.1x6.9x
Mon, 15 Jan 2024US$1.4tUS$204.8b-US$22,497,556,941.0018.8x-63.9x7x
Wed, 13 Dec 2023US$1.3tUS$204.6b-US$22,084,753,624.0019x-59.4x6.4x
Fri, 10 Nov 2023US$1.2tUS$204.3b-US$22,786,529,302.0018.9x-54.1x6x
Sun, 08 Oct 2023US$1.3tUS$207.4b-US$13,060,168,797.0017.2x-96.3x6.1x
Tue, 05 Sep 2023US$1.3tUS$207.5b-US$12,454,516,459.0018.4x-103.9x6.2x
Thu, 03 Aug 2023US$1.1tUS$187.2b-US$14,216,380,818.0013.7x-79.9x6.1x
Sat, 01 Jul 2023US$1.1tUS$186.2b-US$16,042,400,813.0013.7x-70x6x
Mon, 29 May 2023US$1.1tUS$185.9b-US$16,045,777,796.0011.2x-69.9x6x
Wed, 26 Apr 2023US$1.2tUS$198.4b-US$3,227,872,728.0013.1x-364.9x5.9x
Fri, 24 Mar 2023US$1.1tUS$199.5b-US$3,534,604,837.0012.6x-316.2x5.6x
Sun, 19 Feb 2023US$1.2tUS$202.6b-US$64,851,937.0016.5x-17785.7x5.7x
Tue, 17 Jan 2023US$1.2tUS$203.7bUS$1.8b14.5x670.9x5.8x
Thu, 15 Dec 2022US$1.2tUS$203.0bUS$1.5b14.7x771.2x5.8x
Sat, 12 Nov 2022US$1.1tUS$201.0bUS$2.5b14.6x444x5.5x
Mon, 10 Oct 2022US$1.0tUS$206.1bUS$5.4b14.9x190.4x5x
Wed, 07 Sep 2022US$1.0tUS$206.1bUS$6.0b14.5x169.1x5x
Price to Earnings Ratio

169.1x


Total Market Cap: US$1.0tTotal Earnings: US$6.0bTotal Revenue: US$206.1bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average 39.1x202320242025
Current Industry PE
  • Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.4x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
  • Revenues have also declined 7.4% per year, which is driving profits down.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.0096%
Healthcare-0.81%
Biotech-1.83%
Biotech-1.83%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
INSM InsmedUS$136.103.2%
+US$892.0m		78.0%PS72.3x
YDES Breeze Holdings AcquisitionUS$12.504.2%
+US$839.2m		11.0%n/a
MENS Jyong BiotechUS$54.8119.2%
+US$654.0m		n/aPE-1347.7x
MDGL Madrigal PharmaceuticalsUS$437.855.6%
+US$516.4m		77.2%PS18.9x
BBIO BridgeBio PharmaUS$51.765.5%
+US$512.3m		85.9%PS42x

Latest News

NTRA
US$168.25
Natera
7D
1.6%
1Y
42.3%

Optimistic Investors Push Natera, Inc. (NASDAQ:NTRA) Shares Up 25% But Growth Is Lacking

Aug 31
Optimistic Investors Push Natera, Inc. (NASDAQ:NTRA) Shares Up 25% But Growth Is Lacking
ALNY
US$446.51
Alnylam Pharmaceuticals
7D
-1.7%
1Y
70.0%
BBIO
US$51.76
BridgeBio Pharma
7D
5.5%
1Y
85.9%

Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons

Analysts raised BridgeBio Pharma's price target from $62.43 to $63.10, citing stronger-than-expected uptake of Acoramidis (Attruby), major upcoming Phase 3 catalysts, and increased confidence in pipeline diversification and commercial momentum. Analyst Commentary Bullish analysts highlight stronger-than-expected commercial uptake for Acoramidis (Attruby), surpassing initial projections.
MDGL
US$437.85
Madrigal Pharmaceuticals
7D
5.6%
1Y
77.2%

US Patent And EU Expansion Will Secure Future Potential

The consensus analyst price target for Madrigal Pharmaceuticals was raised from $449.57 to $461.43, primarily driven by the EU approval and expanded patent protection for Rezdiffra, which de-risks future cash flows and supports robust sales expectations in a large addressable market. Analyst Commentary Bullish analysts updated their models to reflect the recent EU approval of Rezdiffra, reducing risk and subsequently lowering the discount rate applied to future cash flows.
GILD
US$112.97
Gilead Sciences
7D
-1.6%
1Y
43.0%
AMGN
US$287.71
Amgen
7D
-2.0%
1Y
-13.8%
BIIB
US$132.22
Biogen
7D
-5.1%
1Y
-35.4%
INSM
US$136.10
Insmed
7D
3.2%
1Y
78.0%

Brensocatib's 2025 Launch Will Transform Bronchiectasis Care

Insmed’s consensus price target has surged to $148.44, driven by the FDA approval and strong commercial prospects for Brinsupri, expanded pipeline potential, and robust Phase 2 results for TPIP—underscoring significant upward revisions in revenue and profit expectations. Analyst Commentary Bullish analysts are raising price targets following FDA approval of Brinsupri as the first therapy for non-cystic fibrosis bronchiectasis, citing a broad label with both doses approved, clean safety profile, and inclusion of favorable FEV1 and secondary endpoint data in prescribing information.
BNTX
US$100.00
BioNTech
7D
-9.8%
1Y
13.4%
SMMT
US$23.70
Summit Therapeutics
7D
-9.5%
1Y
82.6%
NBIX
US$139.60
Neurocrine Biosciences
7D
3.1%
1Y
9.9%
VRTX
US$391.02
Vertex Pharmaceuticals
7D
-1.0%
1Y
-21.1%
MRNA
US$24.09
Moderna
7D
-11.2%
1Y
-68.9%
MTSR
US$35.29
Metsera
7D
6.8%
1Y
n/a

Metsera (NASDAQ:MTSR) Is In A Good Position To Deliver On Growth Plans

Jul 31
Metsera (NASDAQ:MTSR) Is In A Good Position To Deliver On Growth Plans